Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib

Brian B. Hasinoff, Daywin Patel, and Kimberley A. O'Hara

Faculty of Pharmacy, Apotex Centre, University of Manitoba, Winnipeg, Manitoba, Canada

Received June 30, 2008; accepted September 24, 2008

ABSTRACT

The anticancer tyrosine kinase inhibitor sunitinib has been shown recently to be cardiotoxic. Using a neonatal rat myocyte model, we investigated various mechanisms that might be responsible for its cardiotoxicity. Sunitinib potently inhibited the enzyme activity of both AMP-activated protein kinase (AMPK) and the ribosomal S6 kinase RSK1 at therapeutically relevant concentrations. Heart tissue with its high energy needs might be particularly sensitive to inhibition of AMPK because of its role as an energy sensor regulating ATP levels. As measured by lactate dehydrogenase release, sunitinib treatment of myocytes caused dose-dependent damage at therapeutic levels. Sunitinib treatment also caused a dose-dependent reduction in myocyte protein levels of the phosphorylated α and β isoforms of the AMPK phosphorylation target acetyl-Coenzyme A carboxylase.

However, myocytes were not protected from sunitinib treatment by pretreating them with the AMPK-activating antidiabetic drug metformin. Sunitinib treatment of myocytes also did not affect cellular ATP levels. Together, these last two results do not suggest a major role for inhibition of AMPK in sunitinib-induced myocyte damage. Dexrazoxane, which is a clinically approved doxorubicin cardioprotective agent, also did not protect myocytes from damage, which suggests that sunitinib did not induce oxidative damage. In conclusion, even though sunitinib potently inhibits AMPK and RSK1, given the extreme lack of kinase selectivity that sunitinib exhibits, it is likely that inhibition of other kinases or combinations of kinases are responsible for the cardiotoxic effects of sunitinib.

Sunitinib (Fig. 1, Sutent) is a new multitargeted oral tyrosine kinase inhibitor that has both antiangiogenic and antitumor activity. It is approved in the United States for treatment of gastrointestinal stromal tumors after disease progression on, or intolerance to, imatinib and for the treatment of advanced renal cell carcinoma (Faiivre et al., 2007). However, two recent clinical studies in patients treated for gastrointestinal stromal tumors or renal cell carcinoma have shown evidence of sunitinib-associated cardiotoxicity as evidenced by heart failure, left ventricular systolic dysfunction, and hypertension (Chu et al., 2007; Telli et al., 2008). Sunitinib joins the other tyrosine kinase-targeted anticancer drugs trastuzumab (Herceptin), and possibly imatinib (Gleevec), dasatinib (Sprycel), sorafenib (Nexavar), and bevacizumab (Avastin) in having cardiotoxic effects (Force et al., 2007; Mego et al., 2007; Menna et al., 2008). Sunitinib inhibits many kinases, including vascular endothelial growth factor receptors, platelet-derived growth factor receptors, stem-cell factor receptor, colony-stimulating factor 1 receptor, FMS-related tyrosine kinase-3, and rearranged-during-transfection receptor tyrosine kinases (Force et al., 2007).

Although sunitinib's anticancer efficacy is probably due to its being a multitargeted kinase inhibitor, its lack of specificity also carries with it a concomitant greater risk of collateral toxicity. A recent study (Karaman et al., 2008) using a competition binding assay investigated the binding of 38 kinase inhibitors to 317 kinases representing more than 50% of the predicted human kinome. Of the seven small-molecule anticancer kinase inhibitors profiled (Karaman et al., 2008) (sunitinib, imatinib, dasatinib, sorafenib, lapatinib, gefitinib, and erlotinib) that are currently approved in the United States, sunitinib is the most promiscuous, binding to 57 and 18% of the kinases tested at 3 and 0.1 μM, respectively. In fact, of the 38 kinase inhibitors tested, only the well characterized promiscuous inhibitor staurosporine was less selective (Karaman et al., 2008).

A recent review (Force et al., 2007) of the possible cardiotoxic mechanisms of tyrosine kinase-targeting drugs hypo-

ABBREVIATIONS: AMPK, AMP-activated protein kinase; ACC, acetyl-Coenzyme A carboxylase; DCF, 2’,7’-dichlorofluorescin; ICRF-187, dexrazoxane.
thesized that inhibition of AMPK through inhibition of prosurvival signals in the heart (Terai et al., 2005; Dyck and Lopaschuk, 2006) and/or inhibition of the ribosomal S6 kinases (RSK), which signals survival through inhibitory phosphorylation of the proapoptotic factor Bad, may, in part, be responsible for the cardiotoxicity of sunitinib. Thus, to investigate these two possible targets, studies were carried out to determine whether sunitinib inhibited AMPK and RSK at clinically relevant concentrations, damaged cardiac myocytes, induced apoptosis in myocytes, and finally whether sunitinib-induced myocyte damage could be prevented by the clinically approved doxorubicin cardioprotective agent dexrazoxane (ICRF-187, Zinecard) (Cvetkovic and Scott, 2005; Hasinoff and Herman, 2007). We showed previously in an in vitro myocyte model that dexrazoxane strongly protects myocytes from doxorubicin-induced damage (Hasinoff et al., 2003; Hasinoff and Herman, 2007).

**Materials and Methods**

**Materials.** Sunitinib malate (ChemPacific, Baltimore, MD) stock solutions were prepared in sterile water. Trypsin, collagenase, and deoxyribonuclease were from Worthington (Freehold, NJ). Dexrazoxane hydrochloride was a gift from Adria Laboratories (Columbus, OH). Unless specified, other reagents were obtained from Sigma (Oakville, Canada). DF-15 medium [with 7.5% (v/v) FBS and 7.5% (v/v) horse serum], fetal bovine and horse serum, penicillin, streptomycin, and Fungizone were obtained from Invitrogen (Burlington, Canada). The errors shown are S.E. Where significance is indicated (p < 0.05), an unpaired t test was used (SigmaPlot; Systat Software, Inc. San Jose, CA). Nonlinear least-squares curve-fitting was done with SigmaPlot.

**Myocyte Isolation and Culture and Epifluorescence Microscopy.** Ventricular myocytes were isolated from 2- to 3-day-old Sprague-Dawley rats as described previously (Hasinoff et al., 2003, 2007; Schroeder et al., 2008). In brief, minced ventricles were serially digested with collagenase and trypsin in Dulbecco’s phosphate-buffered saline, pH 7.4/1% (w/v) glucose at 37°C in the presence of deoxyribonuclease and preplated in large Petri dishes to deplete fibroblasts. The preparation, which was typically greater than 90% viable by trypan blue exclusion, yielded an almost confluent layer of uniformly beating cardiac myocytes by day 2. For the LDH release experiments, the myocyte-rich supernatant was plated on day 0 in 24-well plastic culture dishes (5 x 10^6 myocytes/well, 750 µl/well) in DF-15. On days 2 and 3, the medium was replaced with 750 µl of fresh DF-10 containing 10% (v/v) FBS. To lower the background LDH levels, on day 4, 24 h before the drug treatments, the medium was changed to DF-2 and again on day 5 just before the addition of drugs. The animal protocol was approved by the University of Minnesota Animal Care Committee. The anti-o-actin/Hoechst 33258 staining and imaging by epifluorescence microscopy of fixed myocytes to score for both myofibrillar disruption and for apoptotic nuclei was carried out as we described previously (Hasinoff et al., 2007).

**Drug Treatments and LDH Determination.** Myocytes were either treated with sunitinib for the times indicated or were pretreated with either dexrazoxane or metformin as indicated. Starting on day 6 after plating, samples (80 µl) of the myocyte supernatant were collected every 24 h for 3 days after treatment. The samples were frozen at -80°C and analyzed within 1 week. After the last supernatant sample was taken, the myocytes were lysed with 250 µl of 1% (v/v) Triton X-100/2 mM EDTA/1 mM dithiothreitol/0.1 M phosphate buffer, pH 7.8, for 20 min at room temperature. The total cellular LDH activity, from which the percentage of LDH release was calculated, was determined from the activity of the lysate plus the activity of the three 80-µl samples taken previously. The LDH activity was determined in quadruplicate in a spectrophotometric kinetic assay in 96-well plate in a Molecular Devices (Sunnyvale, CA) plate reader as described previously (Hasinoff et al., 2003, 2007; Schroeder et al., 2008).

**Protein Isolation and Western Blotting Analysis.** Neonatal rat myocytes (2.5 x 10^6) were isolated and plated as described above 5 days before treatment. On the day of treatment, fresh medium was added, and the cells were treated with sunitinib or water for 2 h. Cells were rinsed twice in Dulbecco’s phosphate-buffered saline, pH 7.4, and lysed in buffer (0.125 mM Tris-HCl, pH 6.8, 4% SDS, supplemented with 1 mM sodium orthovanadate and protease and phosphatase inhibitors). The amount of protein in the lysate was determined using the QuantiPro BCA Assay Kit (Sigma) using bovine serum albumin as a reference standard. Sample buffer [5% glycerol/
Results

Effects of Sunitinib on LDH Release in Myocytes. LDH release is a widely used measure of drug-induced damage to myocytes (Adderley and Fitzgerald, 1999; Hasinoff et al., 2007; Schroeder et al., 2008). Using the LDH release assay, we examined the ability of sunitinib to damage myocytes 5 days after isolation (Fig. 1A) when the myocytes would be essentially nonproliferating (Li et al., 1996). As shown in Fig. 1B, at all concentrations between 0.1 and 10 μM, sunitinib significantly increased LDH release (p values of 0.002 for 0.1 μM and <0.001 for all other concentrations, respectively) up to 2.6-fold at 72 h compared with untreated control myocytes. For comparison, we showed in a previous study (Hasinoff et al., 2003) that a 3-h treatment with 1.5 μM doxorubicin resulted in approximately the same percentage of LDH release (～9%) as a 72-h treatment with 1 μM sunitinib (Fig. 1). The submicromolar concentrations of sunitinib used in this study, at which significant LDH release was observed, are within both peak and trough plasma concentrations observed when a therapeutic dose of sunitinib is given (Deeks and Keating, 2006; Faivre et al., 2006). The mean maximum plasma concentration (Cmax) of an oral once-daily dose of 50 mg/day sunitinib is reported to be 0.18 μM (Deeks and Keating, 2006). With repeated daily dosing, trough plasma levels of sunitinib of 0.11 μM are achieved (Faivre et al., 2006).

Attempts to score sunitinib-treated fixed myocytes by epifluorescence microscopy using muscle-specific anti-α-actinin staining along with a Hoechst 33258 counter stain for both myofibrillar disruption and for apoptotic nuclei using methodology described previously (Hasinoff et al., 2007) were not successful. These attempts were confounded by sunitinib causing myocyte detachment from the coverslips even with a 3-h sunitinib treatment. As measured by the number of myocytes per microscopic field, both 5 and 10 μM sunitinib treatment caused a significant loss (p < 0.001) as a 72-h treatment with 1 μM sunitinib (Fig. 1). The percentage disruption was shown in Fig. 2, sunitinib inhibited RSK1 with an IC50 value of 0.36 μM (Kara et al., 2007). This compares with the Ks value in the range of 0.017 to 8.4 μM (Kara et al., 2008).

Inhibition of AMPK and RSK by Sunitinib. The inhibition of AMPK was measured because AMPK is a key regulator of energy metabolism in the heart (Terai et al., 2005; Dyck and Lopaschuk, 2006; Force et al., 2007). As shown in Fig. 2, sunitinib inhibited AMPK with an IC50 value of 0.32 μM, which is within a range that is clinically achieved in plasma (Deeks and Keating, 2006; Faivre et al., 2006). For comparison, a recent redetermination (Karaman et al., 2008) of the binding dissociation constant (K) for the α1 and α2 isoforms of AMPK yielded values of 0.019 and 0.089 μM, respectively. It was also hypothesized (Force et al., 2007) that inhibition of RSK, which signals survival through inhibitory phosphorylation of the proapoptotic factor Bad, may also, in part, be responsible for the cardiotoxicity of sunitinib. As shown in Fig. 2, sunitinib inhibited RSK1 with an IC50 value of 0.36 μM. This compares with the Ks value in the range of 0.14 μM (Karaman et al., 2008). Other RSK isoforms have Ks values in the range of 0.017 to 8.4 μM (Kara et al., 2008).
Sunitinib Inhibits Phosphorylation of ACCα and ACCβ in Myocytes. To confirm our finding that sunitinib inhibited AMPK (Fig. 2), we next determined whether sunitinib functionally inhibited AMPK in neonatal rat myocytes by measuring the inhibition of phosphorylation of ACC, which is one of its phosphorylation targets. The activity of ACC, the rate-limiting enzyme in fatty acid biosynthesis, is primarily regulated by AMPK (Davies et al., 1990; Hardie, 2003, 2004). AMPK phosphorylates ACC on Ser79, which is one of its phosphorylation targets. The activity of ACC, the rate-limiting enzyme in fatty acid biosynthesis, is primarily regulated by AMPK (Davies et al., 1990). Therefore, decreasing AMPK activity may be due to iron-dependent oxygen free radical formation (Hasinoff and Herman, 2007) on the relatively unprotected mitochondrial membrane, where it causes permeabilization of the mitochondria, resulting in cytochrome c release and downstream caspase activation (Li et al., 1997). Because sunitinib treatment increased both LDH release (Fig. 1A) and caspase-3/7 activity (Fig. 4A), we next examined whether protein levels of mitochondrial membrane-associated N-terminal accessible Bax (Capano and Crompton, 2006) were also affected. As shown in Fig. 3, C and D, treatment of myocytes with sunitinib for 2 h at concentrations up to 10 μM did not significantly change Bax protein levels.

Effect of Sunitinib on ATP Levels and Oxidation of DCF in Myocytes. AMPK is a sensor of cellular energy status, and its activation switches on catabolic pathways that generate ATP while switching off ATP-consuming processes (Hardie, 2004). On the other hand, inhibition of AMPK might be expected to decrease ATP levels. Thus, in this functional test, experiments were done to determine whether cellular ATP levels were affected by sunitinib treatment. As shown in Fig. 4B, treatment of myocytes with concentrations of sunitinib from 0.5 to 10 μM for up to 4 h resulted in no significant change in cellular ATP levels.

The oxidation of 2′,7′-dichlorofluorescin to fluorescent 2′,7′-dichlorofluorescein is commonly used to quantitatively measure oxidative stress in cells such as that induced by drugs or hypoxia (Wang et al., 2008). Thus, to investigate whether sunitinib directly or indirectly produced oxidative stress in myocytes, the oxidation of 2′,7′-dichlorofluorescin loaded into myocytes was followed in a fluorescence plate reader. As the results in Fig. 4C show, although treatment with 20 and 50 μM H2O2 significantly (p < 0.001) increased the rate of 2′,7′-dichlorofluorescin oxidation, sunitinib treatment at concentrations from 10 to 40 μM did not significantly affect the rate of 2′,7′-dichlorofluorescin oxidation. Thus, it can be concluded that at least during the short times that these experiments were carried out, the toxic effects of sunitinib on myocytes were not due to oxidative stress.

We showed previously that the clinically approved doxorubicin cardioprotective agent dexrazoxane (ICRF-187, Zindecart, Totect, Savene), which is a prodrug iron chelator, reduced doxorubicin-induced LDH release in a neonatal rat cardiac myocyte model (Hasinoff et al., 2003). Dexrazoxane is clinically used to reduce doxorubicin-induced cardiotoxicity (Cvetkovic and Scott, 2005; Hasinoff and Herman, 2007) and has just been approved in the United States and Europe for the prevention of anthracycline-induced extravasation injury (Hasinoff, 2008). Drug-induced damage to myocytes can involve a series of events, culminating in membrane damage and the release of iron from the cell, which could then involve a secondary indirect iron-induced oxidative stress on other healthy myocytes. Thus, experiments were carried out to determine whether dexrazoxane might also be cardioprotective against sunitinib-induced damage to myocytes. In contrast to the protection against doxorubicin-induced LDH release that we observed previously (Hasinoff et al., 2003), pretreatment of myocytes with 100 μM dexrazoxane did not significantly change the cumulative amount of 5 or 10 μM sunitinib-induced LDH release at 72 h (Fig. 5A). There is considerable evidence that the cardiotoxicity of doxorubicin may be due to iron-dependent oxygen free radical formation (Hasinoff and Herman, 2007) on the relatively unprotected mitochondria.
cardiac muscle. Thus, the fact that dexrazoxane did not protect against sunitinib-induced damage is in accord with the lack of any effect of sunitinib on the oxidation of 2’,7’-dichlorofluorescin (Fig. 4C).

Effect of Metformin and Phenformin on Sunitinib-Induced LDH Release in Myocytes. The antidiabetic biguanide drug metformin is able to activate AMPK in myocytes to induce ACC phosphorylation (Bertrand et al., 2006). Thus, if sunitinib is cytotoxic through its inhibition of AMPK, pretreatment of myocytes with metformin might be expected to protect them from sunitinib-induced damage by increasing pACCα and pACCβ levels. In this third functional test, experiments were carried out in which myocytes were pretreated with either 0.1 or 1 mM metformin for 4 h. This was followed by a 5 μM sunitinib treatment for 3 h, after which both drugs were washed off. As shown in Fig. 5B, metformin did not significantly protect against sunitinib-induced LDH release. Metformin treatment alone compared with control had no significant (p = 0.5) effect on LDH release at 72 h. Similar experiments with the more potent (Bertrand et al.,

---

**Fig. 3.** Treating myocytes with sunitinib reduces pACC levels but has no effect on Bax. A, Western blots for pACCα, pACCβ, ACCα, and ACCβ showing a sunitinib concentration-dependent decrease for each of the pACC isoforms. Myocytes were treated with sunitinib for 2 h, lysed, and subjected to SDS-polyacrylamide gel electrophoresis and Western blotting. The blots were first probed with antibody to pACC, stripped, and reprobed with antibody to ACC. The blots are representative of five independent experiments. B, quantitation of Western blots by densitometry showing a sunitinib concentration-dependent decrease in pACCα and pACCβ protein levels. The results of five independent experiments are reported as the mean ± S.E. The pACCα or pACCβ protein levels were measured relative to ACCα or ACCβ levels, respectively, and normalized to the controls for each isoform. Significance relative to the untreated controls: *, p < 0.05; **, p < 0.01; and †††, p < 0.001. C, Western blots for Bax showing lack of an effect of sunitinib treatment. Myocytes were treated with sunitinib for 2 h, lysed, and subjected to SDS-polyacrylamide gel electrophoresis and Western blotting. The blots were probed with antibodies to Bax and β-actin (as a loading control). D, quantitation of Western blots by densitometry showing a lack of sunitinib concentration-dependence in Bax protein levels. The results of three independent experiments are reported as the mean ± S.E. Significance relative to untreated controls was not achieved with treatment at any sunitinib concentration.

---

**Fig. 4.** Effect of sunitinib on induction of caspase-3/7 apoptosis, ATP levels, and DCF oxidation in myocytes. A, sunitinib treatment induces caspase-3/7 activity in myocytes after 2 and 4 h of treatment. Caspase-3/7-induced rate of increase in luminescence was measured over the first 8 min in a luminescence assay using a proluminescent caspase-3/7 DEVD-aminoluciferin substrate. The results are from an average of 5 wells (10 for the control). Significance relative to the untreated controls: *, p < 0.05; **, p < 0.01; and †††, p < 0.001. B, sunitinib treatment has no effect on cellular ATP levels in myocytes. ATP levels were measured directly after addition of sunitinib (0.1 h) or after 1, 2, or 4 h of treatment. The results are from an average of 4 wells (16 for the control). Significance was not achieved relative to the untreated controls for any treatments. C, sunitinib treatment has no affect on cellular DCF oxidation in myocytes. The change in the rate of fluorescence increase as a result of intracellular oxidation of DCF was measured after the treatment with either H2O2 or sunitinib at the concentrations indicated. The results are from an average of four wells (eight for the control). Relative to untreated controls significance (***, p < 0.001) was only achieved for both H2O2 treatments.
2006) metformin analog phenformin also had no significant effect (data not shown). Thus, even though a 5 μM sunitinib treatment was able to reduce pACCα levels (Fig. 3B), the fact that pretreatment of myocytes with metformin was not protective suggests that sunitinib-induced damage was not AMPK-mediated. It is also noteworthy that a 3-h treatment of myocytes with 5 μM sunitinib (Fig. 5B) caused almost as much LDH release at 72 h as continuous treatment of myocytes for 72 h (Fig. 5B). If the two 20-min washes were effective in reducing intracellular concentrations of sunitinib, this suggests that initiation of sunitinib-induced damage occurred quickly and was not reversed by removal of the drug.

Discussion

The results of this study have shown that either a continuous (Fig. 1) or a 3-h treatment (Fig. 5B) of myocytes with sunitinib causes a dose-dependent LDH release at concentrations that are similar to peak plasma or even trough concentrations observed when a therapeutic once-daily dose of sunitinib is given (Deeks and Keating, 2006; Faivre et al., 2006). Based on the observation that sunitinib bound strongly to both AMPK and RSK kinases (Fabian et al., 2005; Karaman et al., 2008), it had been hypothesized (Force et al., 2007) that inhibition of AMPK and/or inhibition of RSK might be responsible for sunitinib-induced cardiotoxicity. However, because a competition binding assay was used, it had not been shown previously (Fabian et al., 2005; Karaman et al., 2008) whether sunitinib is able to inhibit the enzyme activity of AMPK and RSK. Sunitinib did, in fact, potently inhibit the enzyme activity of both AMPK and RSK1 (Fig. 2), with IC50 values of approximately 0.32 and 0.36 μM, respectively. Because these IC50 values are in the therapeutic plasma concentration range for sunitinib (Deeks and Keating, 2006; Faivre et al., 2006), they both could potentially contribute to the cardiotoxicity (Chu et al., 2007; Telli et al., 2008) of sunitinib. It should be also noted that because the kinase inhibition assays were measured with 50 μM ATP, which is much less than the millimolar intracellular ATP concentrations, the sunitinib IC50 values would increase because of competition with ATP.

AMPK is a sensor of cellular energy status, and its activation controls ATP levels (Hardie, 2004). Because cardiac tissue, unlike other tissues, has only a small reserve of ATP, impaired ATP production could be a factor in sunitinib-induced cardiotoxicity. To determine whether sunitinib could functionally affect one of the phosphorylation targets of AMPK, its effect on the phosphorylation of ACC in myocytes was studied. Although sunitinib did decrease pACCα levels (Fig. 3B) in a dose-dependent manner, significance was only achieved at a sunitinib concentration of 5 μM. Because this concentration is approximately 25-fold greater than therapeutically achievable plasma levels (Deeks and Keating, 2006; Faivre et al., 2006), it is unclear whether therapeutic levels could significantly inhibit AMPK to contribute to the cardiotoxicity of sunitinib. However, it must be noted that these experiments were carried out with a 2-h treatment of the myocytes with sunitinib, whereas patients are dosed daily with sunitinib for extended periods of time. Thus continual inhibition of AMPK activity by sunitinib as a result of long-term dosing could have more subtle effects in inducing cardiotoxicity. In addition, the cellular levels of sunitinib that are achieved with daily dosing are unknown and could be higher than plasma levels. Thus, we cannot rule out that more subtle cardiotoxic effects can occur because of long-term partial inhibition of AMPK when patients are treated with sunitinib for extended periods of time. It should also be noted that sunitinib causes hypertension (Deeks and Keating, 2006), which may modify cardiac energy metabolism and make the heart more sensitive to inhibition of AMPK.

The relative decrease in the levels of mitochondrial-associated pACCβ was not significantly different from those observed for pACCα (Fig. 3B), and thus sunitinib does not preferentially affect pACCβ in mitochondrial-rich myocytes.

A second functional test of whether inhibition of AMPK by sunitinib may be causing cardiotoxicity was carried out by measuring its effect on intracellular levels of ATP in myocytes (Fig. 4B). However, the lack of any significant effects, at least with this short 4-h treatment, suggests that sunitinib did not induce damage in myocytes by reducing ATP levels. As measured by caspase-3/7 activity, sunitinib treatment did induce a rapid apoptotic response in myocytes (Fig. 4A), indicating that this pathway may be significant in producing cardiotoxicity. However, Bax levels were not significantly changed by sunitinib treatment (Fig. 4B), indicating that there is no role for this pathway in the induction of apoptosis. It also seems that as measured by oxidation of intracellular oxidation of DCF, that sunitinib did not cause oxidative damage to myocytes. This conclusion was also supported.
by experiments in which myocytes were pretreated with the clinically approved doxorubicin cardioprotective agent dexrazoxane, which showed that dexrazoxane provided no significant protective effect (Fig. 5A) against sunitinib-induced damage. This result suggests that dexrazoxane would not be clinically useful as a sunitinib-protective agent. In a final functional test, pretreatment of myocytes with either the antidiabetic drug metformin or phenformin did not protect myocytes from sunitinib. Metformin and phenformin activate AMPK (Bertrand et al., 2006), and its activation could in principle partially compensate for the AMPK-inhibitory effects of sunitinib. The failure of metformin and phenformin to protect myocytes also suggests that sunitinib-induced damage to myocytes is not AMPK-mediated.

In this study, we investigated the inhibition of only two potential kinase targets (AMPK and RSK1) that might be involved in the cardiotoxicity of sunitinib. In a recent extensive profiling of the binding of 38 kinase inhibitors to 317 kinases representing more than 50% of the predicted human kinome, sunitinib, as measured by its $K_d$ value, was the second most promiscuous inhibitor (next only to staurosporine) (Karaman et al., 2008). At a sunitinib concentration of 0.1 μM, which is approximately equal to therapeutic plasma levels (Deeks and Keating, 2006; Fairev et al., 2006), sunitinib strongly bound to 18% of the kinases tested (Karaman et al., 2008). If this degree of binding, and hence inhibition, is maintained over the whole human kinome of more than 500 proteins, this result suggests that approximately 90 kinases are potently inhibited at therapeutic plasma levels of sunitinib. Inhibition of which kinase, or even which combination of kinases, is responsible for the cardiotoxicity may be very difficult to ever definitively identify. Although this study did show that sunitinib inhibited AMPK within its therapeutic range, other functional tests of downstream effects of this inhibition were, for the most part, not supportive of a major role for sunitinib inhibition of AMPK. Balanced against this, it should be noted that all of these functional tests were carried out over a period of a few hours only.

References


Address correspondence to: Dr. Brian Hasinoff, Faculty of Pharmacy, Apotex Centre, University of Manitoba, 750 McDermot Avenue, Winnipeg, Manitoba R3E 0T5, Canada. E-mail: b_hasinoff@umanitoba.ca